In glioblastoma, diminished therapeutic response to CTLA-4/PD-L1 mAbs in IDO−/− mice compared to WT mice was observed, indicating the requirement for germline IDO to achieve maximal survival benefit from immune checkpoint therapy against brain tumors (196). Here, IDO1 is linked to glioblastoma.